189 results about "Nsclc cell" patented technology

The present invention relates to a double-stranded RNA and its application for inhibiting mammalian tumor cell. Said invention adopts the RNA interference technique to introduce the externally-synthetic double-stranded RNA into mammalian tumor cell by means of combination of non-viral carrier and / or viral carrier, and can inhibit the expression of epidermal growth factor receptor so as to change NSCLC cell biological character and raise the sensitivity of mammalian tumor cell to radiation therapy and chemical therapy. Said invented double-strand RNA can be used for preparing antitumor biological preparation and antitumor medicine to make direct injection in tumor body in travenous medication for effectively inhibiting tumor growth.

The invention relates to a marine bacillus and its polypeptide with antitumor activity. The strain is preserved at China Center for Type Culture Collection in Wuhan, and its preservation number is CCTCC M 2013063. A novel marine bacillus polypeptide with anti-tumor activity is obtained from a fermentation product of the strain. By means of an MTT method, the invention finds that the polypeptide has an obvious proliferation inhibition effect on human hepatoma carcinoma cell BEL-7402, human breast cancer cell MCF-7, human glioma cell U251, human non-small-cell lung cancer cell A549 and other tumor cells, has relatively small cytotoxicity on human fibroblast HFL1, and can be applied in drugs treating human liver cancer, gliomas, lung cancer and breast cancer.

The invention relates to a target drug feeding system with combination of nano-silver and curcumin or a curcumin derivative and belongs to the technical field of biological medicines. The nano-silver target drug feeding system particularly takes an aptamer as a target point; the curcumin or the curcumin derivative or the nano silver is used as a combined anti-tumor drug and is polymerized to the outer surface of a biodegradable high-molecular polymer nano-system (PNS) by the aptamer to synthesize an aptamer-PNS polymer which is used as a shell; the PNS simultaneously encapsulates the curcumin or the curcumin derivative and the nano silver, so as to prepare the nano-silver target drug feeding system which is loaded with active components including the curcumin or the curcumin derivative and improve the solubility and bioavailability of the curcumin and the curcumin derivative; meanwhile, drugs can be targeted into non-small-cell lung cancer cells or prostate cancer cells; the anti-tumor effects of the curcumin or the curcumin derivative and the nano silver are expressed so that the target drug feeding and drug slow releasing effects are realized; the nano-silver target drug feeding system is used for preventing and treating lung cancers and prostatic cancers, the treatment effect is improved and the toxic side effect is reduced.

The invention discloses a low-toxicity 1,8-naphthalimide derivative and a synthetic method and application thereof. The synthetic method of the 1,8-naphthalimide derivative mainly comprises the following steps: dissolving amonafide and 2-fluorobenzoyl chloride in an organic solvent and reacting; and after reaction is finished, removing a solvent to obtain a coarse product as a target object. Testsshow that the derivative has remarkable bioactivity, and particularly has remarkable inhibition activity to non-small cell lung cancer cell strains HCC-827 and other tumor cell strains, moreover, toxic and side effects of human normal cells are small, and thus, the 1,8-naphthalimide derivative is expected to be developed into a targeted therapy drug. The structure of the 1,8-naphthalimide derivative is as shown in a formula (I) as shown in the specification.

The invention belongs to the field of genetic engineering and particularly relates to application of long non-coding RNA (Ribonucleic Acid) uc003hsl.1 in preparation of drugs for treating non-small cell lung cancer. The influence on the apoptosis, propagation, drug susceptibility and the like of non-small cell lung cancer cells is caused through changing the expression of the long non-coding RNA uc003hsl.1, so that through lowering the expression of the long non-coding RNA uc003hsl.1, the apoptosis of the non-small cell lung cancer cells can be promoted, the propagation of the non-small cell lung cancer cells can be inhibited, and the susceptibility to chemotherapy drugs of the non-small cell lung cancer cells can be enhanced.

The invention discloses a non-small cell lung cancer cell line, and an establishment method and application thereof. The human non-small cell lung cancer cell line is preserved in China Center for Type Culture Collection with an accession number of CCTCC NO: C2012128. The establishment method comprises the following steps: step 1, acquiring a fresh clinical human non-small cell lung cancer surgical specimen, cutting the specimen into small blocks with a size of 20 to 50 mg and inoculation mammals with the block through subcutaneous puncture; and step 2, in 70 to 90 days after the puncture-inoculation, killing a tumor-bearing animal, taking tumor tissue out of the tumor-bearing animal and carrying out primary culture and subculture of cancer cells. According to the invention, the human non-small cell lung cancer cell line has the advantages of stable properties, capability of realizing stable multiple passage, a high tumor formation rate, a short latent period and good homogeneity; meanwhile, the human non-small cell lung cancer cell line has acquired drug resistance to gefitinib, can be used to analyze correlation between in-vitro and in-vivo drug sensibilities and drug resistance and is the ideal cell line for basic research on and preclinical application of human non-small cell lung cancer.

The invention discloses a novel anti-crizotinib human non-small cell lung cancer cell strain which is named as H3122-CR23 and has an accession number of CCTCC No. C201780. The cell strain has F1174C mutation in an ALK kinase area. The cell strain H3122-CR23 is applicable to research on the morphological and biological characteristics of human anti-crizotinib non-small cell lung cancer cells, research on the drug resistance mechanisms of tumors, development of drugs for drug resistance reversal of tumors, analysis of the susceptibility of antitumor drugs, screening and assessment of antitumor drugs, research on more efficient tumor treatment methods, etc., has high application value in scientific research and production, and is expected to produce good scientific research, economic and social benefits.

The invention discloses a benzimidazole-containing Tr*ger's base type compound as well as a preparation method and application thereof. A structural formula of the compound is shown as a formula 3; the compound is prepared by carrying out aldimine condensation reaction on 2,8-dialdehyde-Tr*ger's base and substituted o-phenylenediamine. An in-vivo experiment shows that the benzimidazole-containingTr*ger's base type compound has relatively high inhibition activity on non-small cell lung cancer cells (A549), triple-negative breast cancer cells (231) and triple-positive breast cancer cells (MCF-7), and has low toxicity in human normal cells; the benzimidazole-containing Tr*ger's base type compound can be mixed with human body acceptable acid-forming salt or a medical carrier to form an anti-tumor drug. The invention provides a candidate compound for researching and developing a novel drug for treating triple-negative and triple-positive breast cancer and non-small cell lung cancer. The formula 3 is shown in the description.

The invention discloses a preparation method of lysimachia capillipes saponin A. The preparation method mainly comprises the following steps: selecting a lysimachia capillipes plant raw material, extracting the lysimachia capillipes plant raw material by adopting a water or ethanol-water mixed solvent, further purifying by adopting filler such as macroporous resin to obtain a total saponin extract rich in saponin B and C, dissolving the total saponin extract in an appropriate amount of alkaline solution, reacting at 40 to 80 DEG C, neutralizing by utilizing appropriate amount of acid, and further purifying the obtained hydrolysate by adopting filler such as macroporous resin, silica gel, reverse phase silica gel and the like, to obtain a lysimachia capillipes sapoonin A extract with content more than 90 percent. The invention also discloses an application of the lysimachia capillipes saponin A. The compound of the lysimachia capillipes saponin A has a remarkable inhibition effect on 11 human tumor cell lines such as A549 non-small cell lung cancer cells, SMMC-7721 human liver cancer cells, PC3 human prostate cancer cells and the like, has a broad-spectrum anti-cancer effect, and can be used as a drug or a medicine composition to treat malignant tumors.

The invention discloses a compound lithocarolsA-F, a preparation method and application thereof in preparation of antitumor drugs. The compound lithocarolsA-F is isolated from a fermentation culture of marine fungi Phomopsis lithocarpus FS508. Experiments prove that the IC50 values of the compound lithocarolsA-F on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A549 are 10.5-87.7 muM, showing that the compound lithocarolsA-F has relatively significant antitumor activity and can be used for preparing antitumor drugs.

2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and / or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.

The invention discloses a low-toxicity 1,8-naphthalene dimethimide derivative as well as a preparation method and application thereof. The preparation method of the 1,8-naphthalene dimethimide derivative mainly comprises the following steps: dissolving amonafide and 3-fluorobenzoyl chloride into an organic solvent, performing reaction, and removing the solvent after reaction to obtain a target crude product. The experiment of the applicant indicates that the derivative has remarkable bioactivity, particularly has remarkable inhibition activity on a non-small cell lung cancer cell strain HCC-827 and other tumor cell strains, has smaller toxic and side effects on human normal cells, and is expected to be developed into a targeted therapy medicine. The structure of the 1,8-naphthalene dimethimide derivative is as shown in the formula (I): (the formula is as shown in the description).

The invention discloses a chromone skeleton-containing polycyclic compound as well as a preparation method and application thereof. The preparation method comprises the following steps: with 3-iodochromone compounds and norbornene as building blocks and palladium acetate as a catalyst, carrying out a [2 + 2 + 1] domino cycloaddition reaction with benzyl bromide compounds in an organic solvent to obtain a series of polycyclic compounds containing chromone skeletons, wherein diastereostereoselective change of the product is realized by adjusting the solvent. The chromone skeleton-containing polycyclic compound contains a chromone skeleton with potential biological activity, can provide a compound source for biological activity screening, and has important application value for drug screeningand pharmaceutical industry. Meanwhile, tumor growth inhibition activity screening is carried out on human non-small cell lung cancer cells (A549) and human hepatoma carcinoma cells (HepG2) of two tumor cell strains by the compound, and the compound is found to have certain tumor cell growth inhibition activity and can be applied to preparation of anti-tumor drugs.

The invention discloses camphoryl pyrimidines, and a preparation method and an anti-tumor activity study thereof. With camphor as a raw material and under an alkaline catalysis condition, a series ofalpha,beta-unsaturated ketones are obtained through aldol condensation reaction of camphor with different aromatic aldehydes respectively, a series of camphoryl pyrimidines are obtained through annulation reaction of alpha,beta-unsaturated ketones with guanidine hydrochloride through catalysis of potassium tert-butoxide, and the anti-tumor activity of the synthesized camphoryl pyrimidines is studied. Experiments show that the camphoryl pyrimidines have good inhibitory activity on human multiple myeloma cells (RPMI-8226), human breast cancer cells (MDA-MB-231) and human non-small cell lung cancer cells (A549), have less toxicity on normal cell human gastric mucosa cells (GES-1), and have potential anti-tumor application value.

The invention provides jervine steroid alkaloid derivatives. Steroidal alkaloids, namely veratramine, jervine and cyclopamine are taken as raw materials, and subjected to chemical modification to obtain ninety-three derivatives, which comprise N-hydrocarbon and N-acylate. In the invention, cell lines such as human pancreatic cancer cells B*PC-3 and SW1990, a small cell lung cancer cell NCI-H466, a non-small cell lung cancer cell NCI-H157 and the like are selected, the antitumor activity of all compounds are evaluated by an MTT method, and results show that the derivatives 41, 43 and 58 have obvious antitumor activity, the other eight derivatives 10, 18, 19, 38, 45, 48, 50 and 92 also show medium antitumor activity, and the derivatives can be used for preparing antitumor medicaments.

The invention belongs to the field of gene engineering, and particularly relates to application of LINC00961 to prediction of non-small-cell lung cancer (NSCLC) prognosis and treatment of target spot medicine. In the NSCLC, down-regulation of the LINC00961 is closely related to clinical stages and tumor sizes, and is closely related to patient prognosis at the same time. The invasion, migration and the like of NSCLC cells are influenced by changing expression of the LINC00961, so that the LINC00961 expression is enhanced, and the invasion and migration of the NSCLC cells can be restrained.

Tumor-Treating Fields elicit a conditional vulnerability to PARP inhibitors (e.g., Olaparib) in certain cancer cells such as non-small cell lung cancer (NSCLC) cell lines. This conditional vulnerability is exploited in a method of killing cancer cells that comprises delivering a PARP inhibitor to the cancer cells and applying an alternating 80-300 kHz electric field to the cancer cells. At least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. In some embodiments, an additional step of treating the cancer cells with a radiation therapy is added to the method. In some embodiments, the frequency of the alternating electric field is between 100 and 200 kHz.

The invention discloses a nano-silver anti-cancer composition for treating lung cancer. The nano-silver anti-cancer composition for treating the lung cancer comprises the following components in concentration: 12-200mg / kg spherical nano-silver powder, 700-800mg / kg pharmaceutically acceptable dispersing agent carbopol, 700-800mg / kg triethanolamine and 2.8-3.2g / kg of glucose, wherein pure water is taken as a diluent, and purity of silver in the spherical nano-silver powder is more than or equal to 99.99%, and particle diameter of silver particles is 1-5nm. Experimental results show that the nano-silver anti-cancer composition can completely inhibit proliferation of human non-small cell lung cancer cells A549 and can cause death of all the cells. The nano-silver anti-cancer composition disclosed by the invention can be used for treating the lung cancer and even can be applied to preparation of a medicine used for treating the lung cancer.

The invention relates to a fluorescent probe for quickly diagnosing and accurately treating non-small cell lung cancer (NSCLC), particularly fluorine boron pyrrole compounds and application thereof. The fluorine boron pyrrole compounds are disclosed as General Formula I, and are used as the fluorescent probe for diagnosing and treating NSCLC. The fluorophore and lung cancer cells are used for locating the label of the ligand, and the probe can specifically select the NSCLC cells. The overexpressed glutathione in the lung cancer cells breaks the disulfide bond in the probe, the drugs can be slowly released in the cancer cells to generate the target treatment effect, and meanwhile, near-infrared fluorescence can be emitted, thereby generating the double effects of diagnosis and treatment. The fluorescent probe can trace the alveolar epithelial cells with pathological changes at high sensitivity, and can release the drugs to the cancer tissues in a more accurate mode, thereby lowering the general untoward effects of the drugs and enhancing the living quality of the patient. The research has important biomedical meanings for the diagnosis and treatment modes of NSCLC and the research of the drug-resistance mechanism of the NSCLC cell strain.

The invention relates to naphthopyrone compounds, and a preparation method and application thereof, belonging to the field of pharmaceutical chemistry. The six naphthopyrone compounds have the advantages of simple preparation process, simple raw materials, convenient after-treatment, high yield and high purity (up to 98% or above), and the structure can be verified through nuclear magnetism and mass spectroscopy. After the six naphthopyrone compounds are used for preparing antineoplastic drugs and the obtained antineoplastic drugs are subjected to anticancer activity research on A549 cells (human non-small cell lung cancer cells), the research result on the apoptosis by the real-time cell analysis technique (RTCA) proves that the compounds L2 and L3 have strong killing actions on the A549 cells, the compound L1 has weaker killing actions, and the compounds L4, L5 and L5 have the weakest killing actions. Therefore, the invention has substantial meanings for research into screening of the antineoplastic drugs of the compounds.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to IncRNA application, a kit and medicine. According to the application of IncRNA for preparing the kit for diagnosis and / or prognosis evaluation of NSCLC. The nucleotide sequence of the IncRNA is shown in SEQ ID No.1. The IncRNA is highly expressed in plasma before the NSCLC patient surgery, after the surgery, the expression level in the plasma is remarkably lowered, the expression levels in the NSCLC cancer tissue, the NSCLC patient plasma and the NSCLC cells are all remarkably higher than those ofpara-carcinoma tissue, healthy human plasma and normal bronchus epithelial cells. The study result suggests that the IncRNA has the remarkable capability for inhibiting the NSCLC cell tumor activity,and the IncRNA is newly found for tumor inhibition.

The invention discloses application of a Fascaplysin compound, and particularly relates to application of the Fascaplysin compound in preparation of a ferroptosis inducer, a medicine for improving the concentration of iron ions in cells and an anti-tumor medicine. The Fascaplysin compound can induce the occurrence of ferroptosis, regulates the death of non-small cell lung cancer cells in a novel mode of promoting cell death, can improve the concentration of the iron ions in the cells, is an effective ferroptosis inducer, and can be used for preparing and developing the anti-lung cancer medicine.

The invention belongs to the field of genetic engineering and particularly relates to an application of a circular RNA circ-0058040 to preparation of a drug for treating a non-small cell lung cancer.Proliferation, apoptosis and drug susceptibility of a non-small cell lung cancer cell are influenced by changing expression of the circular RNA circ-0058040; the application illustrates that the proliferation of the non-small cell lung cancer cell can be inhibited by the expression of the circular RNA circ-0058040; and the susceptibility of the non-small cell lung cancer cell to a targeted drug can be enhanced.

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol / L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol / L. The application is helpful for the development of novel antitumor drugs.

The invention discloses an application of MAGE-A9 in the preparation of lung cancer treatment drugs. The MAGE-A9 is a target for non-small cell lung cancer gene therapy, and the drugs are designed against the target. Influences of down-regulation of MAGE-A9 gene expression on NSCLC (non-small cell lung cancer) cell invasion, migration and other biological behaviors are researched in test of in vitro environment, and a result of the researches shows that a specific siRNA sequence can effectively inhibit expression of the MAGE-A9 protein in the NSCLC cell strains SPC-A-1 and NCI-H1975. After the MAGE-A9 expression is inhibited through RNA interference, propagation of the SPC-A-1 and NCI-H1975 cells is slow, apoptosis increases, and the cell migration and invasion ability is reduced. The MAGE-A9 is the target for non-small cell lung cancer gene therapy, and can be widely applied in the preparation of the lung cancer treatment drugs.

The invention discloses a polyketone compound Lithocarpin E-G as well as a preparation method and application of the polyketone compound Lithocarpin E-G. The compound Lithocarpin E-G is separated andprepared from a fermentation culture of a marine fungus Phomopsis lithocarpus FS 508. Proved by tests, the IC50value range of the compound Lithocarpin E-G on liver cancer cell HepG-2, breast cancer cell MCF-7, glioma cell SF-268 and non-small cell lung cancer cell A549 is 6.3-91.6 mu M, the anti-tumor activity is relatively obvious, and the compound Lithocarpin E-G can be used for preparing anti-tumor drugs.

The invention discloses an application of PLPP4 ((phospholipid phosphatase 4) as a diagnosis, treatment and prognosis target for NSCLC (non-small-cell lung carcinoma). High expression of PLPP4 in tumor tissue and cell lines of NSCLC is discovered, high expression of PLPP4 in lung malignant tumor tissue is related to low clinical pathological grades as well as short overall survival time and progression-free survival time of a patient, in-vitro NSCLC cell proliferation and in-vivo tumorigenesis can be affected by silencing PLPP4, and all the information indicates that PLPP4 can serve as the diagnosis, treatment and prognosis target for NSCLC. Primers performing fluorescent quantitative detection on PLPP4 are taken as reagents for diagnosis and prognosis of NSCLC, and LNA modified sisiRNA capable of specifically silencing PLPP4 is taken as a treatment medicine for NSCLC.

The invention discloses base-Schiff base derivatives. A structural general formula of the base-Schiff base derivatives is as shown in a formula [I] as shown in the specification, and the base-Schiff base derivatives are produced by subjecting raw materials of p-bromoaniline, paraformaldehyde, n-butyllithium, p-aminobenzoic acid, substituted o-phenylenediamine and the like to a condensation reaction. The base-Schiff base derivatives fluoresce, emit blue light, and have obvious aggregation-induced emission and solid-state emission, part of compounds have capability of recognizing Al3+, and two compounds have good effects of inhibiting one or two kinds of triple-negative breast cancer cells and liver caner cells, and have small toxicity to normal cells; and three compounds have certain degrees of effects of inhibiting one or more kinds of non-small cell lung cancer cells, triple-negative breast cancer cells and liver cancer cells.

The invention relates to an amide ethyoxyl-beta-D-glucoside compound and a preparation method and application of the amide ethyoxyl-beta-D-glucoside compound. A structural general formula of the amide ethyoxyl-beta-D-glucoside compound is as shown in formula I in the description, wherein R is selected from straight-chain alkyl. According to the amide ethyoxyl-beta-D-glucoside compound and the preparation method and the application of the amide ethyoxyl-beta-D-glucoside compound, disclosed by the invention, the amide ethyoxyl-beta-D-glucoside compound which is as shown in the formula I is synthesized for the first time, and obvious inhibitory activity of the amide ethyoxyl-beta-D-glucoside compound on two types of tumor cells: a human non-small cell lung cancer cell H460 and a human hepatoma carcinoma cell HEP3B is verified, so that the amide ethyoxyl-beta-D-glucoside compound can be used for preparing drugs for resisting tumors; meanwhile, the steps of a synthetic route of the amide ethyoxyl-beta-D-glucoside compound are simple, and the achieving rate is high.

The invention discloses an osimertinib-resistant human non-small cell lung cancer cell strain which is named as osimertinib-resistant human lung cancer cell line H1975 / OR, and has a preservation number of CCTCC NO:C2019300. According to the cell strain, EGFR exon21: c.T2573G: p.L858R mutation and exon20: c.C2369T: p.T790M mutation which are sensitive to osimertinib are reserved, RB1 gene deletionoccurs after drug resistance is acquired, and a small cell lung cancer phenotype is shown. The osimertinib-resistant human non-small cell lung cancer cell strain H1975 / OR disclosed by the invention can be used for researching the morphological and biological characteristics of osimertinib-resistant human non-small cell lung cancer cells, studying a tumor drug resistance mechanism, analyzing the sensitivity of the anti-tumor drug, screening and evaluating the anti-tumor drug, developing a tumor drug resistance reversal drug and studying a more effective tumor treatment method, and can be used for discussion of a small cell lung cancer transformation mechanism after EGFR-TKIs treatment and research of related signal channels, has high scientific research and production application values, and is expected to produce good scientific research, economic and social benefits.